Hikma Pharmaceuticals (LSE:HIK) delivered a solid first-half performance for 2026, with group revenue increasing 4% to $1.728 billion and core operating profit rising 9% to $405 million. Growth was supported by a strong performance in the Branded division, alongside resilient contributions from the Injectables and Hikma Rx businesses. Although reported profit attributable to shareholders edged lower, the company improved cash generation, retained a strong balance sheet, increased its interim dividend and continued its $250 million share buyback programme.
The group accelerated investment in research and development as well as sales and marketing during the period, submitting 48 products for approval and launching 43 new medicines. Hikma also expanded strategic partnerships, particularly across the Middle East and North Africa, to strengthen its product pipeline and broaden its portfolio. Management highlighted the introduction of a new geographically aligned leadership structure, the planned exit from its 503B compounding operations, continued supply chain efficiency initiatives and recent board changes. The company reaffirmed its full-year outlook, expecting modest revenue growth and higher core operating profit, reflecting confidence in its long-term strategy.
The investment outlook remains supported by solid profitability, a healthy balance sheet and positive long-term strategic initiatives, although weaker cash generation and lower cash conversion have tempered the financial picture. Technically, the shares continue to trade in a strong upward trend, but overbought indicators suggest the potential for increased short-term volatility. An attractive valuation, supported by a low price-to-earnings ratio, a dividend yield of around 3.7% and an ongoing share buyback programme, reinforces the company’s longer-term investment appeal.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a UK-headquartered multinational pharmaceutical company specialising in branded and generic medicines. The business has established operations across North America, Europe and the Middle East and North Africa, with particular strength in injectable medicines and complex generic pharmaceuticals.
The company is recognised as a leading supplier of branded medicines across the MENA region, one of the largest providers of generic injectables in the United States and an expanding participant in the European injectables market. Through continued investment in research, manufacturing and commercial capabilities, Hikma aims to broaden patient access to high-quality medicines worldwide.
Leave a Reply